A recent article in Drug Target Review highlights how 3D cell culture models are revolutionizing pre-clinical drug development by providing more accurate, human-relevant data earlier in the pipeline. These models better replicate human tissue complexity and immune interactions, offering a significant leap beyond traditional 2D cultures and animal models.
At PrecliniX, we are advancing this evolution with our ex vivo 3D testing platform, designed to assess drug efficacy using real patient samples. Our system not only mirrors the immune composition of patients more precisely but also delivers actionable results in under five days, dramatically accelerating decision-making in drug development.
By combining sophisticated 3D tissue models with AI-driven analysis, PrecliniX reduces reliance on animal testing, helping partners achieve both scientific and ethical goals.
This growing industry shift toward patient-specific, high-throughput platforms underscores our mission: to make drug development faster, more predictive, and more humane.
